UK maternity charity MIDIRS, renowned for its evidence-based information resources for health care professionals, announced that a total of 15,792,079 units of information had been delivered to customers during 2008.
Despite a downturn in the number of full-time practising midwives in the UK and the continuing economic crisis that has seen a decline in consumer confidence over the past 12 months, MIDIRS determination to meet its mission of assisting in the improvement of maternity care by producing and delivering a range of practical resources based on the best evidence-based information available, has paid off.
Andy Fisher, MIDIRS Business Manager said: 'There are huge demands on health care professionals at the moment, which has made MIDIRS doubly committed to supporting them in their practice and studies by providing improved information services which are both practical and affordable. Considering that 2008 was a challenging year in many respects, we are delighted that MIDIRS logistical performance during the last 12 months has remained positive'.
Source
MIDIRS
четверг, 17 ноября 2011 г.
четверг, 10 ноября 2011 г.
"Cosmetic Surgery And The Use Of Antidepressant Medication"
It has been proven that plastic surgery can improve self-esteem, but can it also act as a natural mood enhancer? A significant number of patients stopped taking antidepressant medication after undergoing plastic surgery, according to a study presented at the American Society of Plastic Surgeons (ASPS) Plastic Surgery 2006 conference in San Francisco.
"Plastic surgery patients are taking a proactive approach in making themselves happier by improving something that has truly bothered them," said Bruce Freedman, MD, ASPS Member Surgeon and study author. "While we are not saying that cosmetic plastic surgery alone is responsible for the drop in patients needing antidepressants, it surely is an important factor."
In the study, 362 patients had cosmetic plastic surgery - 17 percent or 61 patients were taking antidepressants. Six months after surgery, however, that number decreased 31 percent, down to 42 patients. In addition, 98 percent of patients said cosmetic plastic surgery had markedly improved their self-esteem.
All of the patients, who were primarily middle-aged women, had an invasive cosmetic plastic surgery procedure such as breast augmentation, tummy tuck or facelift. The authors did not identify any other major life changes that may have affected patients' use of antidepressants.
"We have just begun to uncover the various physical and psychological benefits of plastic surgery," said Dr. Freedman. "By helping our patients take control over something they were unhappy about, we helped remove a self-imposed barrier and ultimately improved their self-esteem."
For referrals to ASPS Member Surgeons certified by the American Board of Plastic Surgery visit plasticsurgery/ where you can also learn more about cosmetic and reconstructive plastic surgery.
The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. With more than 6,000 members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.
Note: The study "Cosmetic Surgery and the Use of Antidepressant Medication" is being presented in electronic format, Sunday, Oct. 8 - Tuesday, Oct. 10, at the Moscone Convention Center, San Francisco.
Contact: LaSandra Cooper
American Society of Plastic Surgeons
"Plastic surgery patients are taking a proactive approach in making themselves happier by improving something that has truly bothered them," said Bruce Freedman, MD, ASPS Member Surgeon and study author. "While we are not saying that cosmetic plastic surgery alone is responsible for the drop in patients needing antidepressants, it surely is an important factor."
In the study, 362 patients had cosmetic plastic surgery - 17 percent or 61 patients were taking antidepressants. Six months after surgery, however, that number decreased 31 percent, down to 42 patients. In addition, 98 percent of patients said cosmetic plastic surgery had markedly improved their self-esteem.
All of the patients, who were primarily middle-aged women, had an invasive cosmetic plastic surgery procedure such as breast augmentation, tummy tuck or facelift. The authors did not identify any other major life changes that may have affected patients' use of antidepressants.
"We have just begun to uncover the various physical and psychological benefits of plastic surgery," said Dr. Freedman. "By helping our patients take control over something they were unhappy about, we helped remove a self-imposed barrier and ultimately improved their self-esteem."
For referrals to ASPS Member Surgeons certified by the American Board of Plastic Surgery visit plasticsurgery/ where you can also learn more about cosmetic and reconstructive plastic surgery.
The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. With more than 6,000 members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.
Note: The study "Cosmetic Surgery and the Use of Antidepressant Medication" is being presented in electronic format, Sunday, Oct. 8 - Tuesday, Oct. 10, at the Moscone Convention Center, San Francisco.
Contact: LaSandra Cooper
American Society of Plastic Surgeons
четверг, 3 ноября 2011 г.
Mother Gives Birth To Twins With Different Fathers, US
11-month old Dallas-born twins Justin and Jordan have different fathers, a phenomenon known as heteropaternal superfecundation that is so rare there
are only a handful of documented cases in the world.
Their parents Mia Washington and her fianc?©e James Harrison went public with their news last week when they contacted FOX4 to tell their
story.
Admitting she was having an affair with another man at the time the twins were conceived, Washington said she was shocked that it had happened to
her:
"I have twins, but they're by different fathers," she told the TV news company.
Washington and Harrison noticed that the twins had different facial features and decided to have a paternity test. They went to Dallas DNA Lab Clear
Diagnostics who said they had never seen a result like this before and that there was a 99.999 per cent chance that Justin and Jordan were fathered by
different men.
The highly probable result is that Jordan is Harrison's biological son and Justin's biological father is the man Washington had an affair with.
Lab Clear Diagnostics' president Genny Thibodeaux described the news as "very crazy", and "most people don't believe it can happen".
Dr Chris Dreiling, from the Paediatric Association of Dallas, who has not met the family, told Fox News that a woman can release more than one egg
during ovulation, and if she has intercourse with more than one partner at around that time, then sperm from different partners can fertilize each egg:
"Because sperm cells take a while to travel and eggs take a while to travel there can be an overlap," said Dreiling, explaining that it was a very rare
event and likely to be "the only time that we will ever see this occur in the city of Dallas".
Harrison said he will bring up the two boys as his own. He said he has forgiven his fianc?©e and promised to stay with her.
He said they are taking it day by day, "it's going to take time to build that trust like we had", he added.
Washington said she felt wary at first, thinking he would try but then give up and leave. But she said that has not happened.
"James is a good man; he's a great father and genuinely loves both of the twins," said Washington, adding that as far as she was concerned he was the
father of both boys because "he's the one there every morning when they get up and every night when they go to sleep".
Washington said she regrets her mistake and wants other people to know that this can happen.
"Don't put yourself in my shoes, because it can hurt and it does hurt, but you still have to go on with life". She had this advice for other women:
"Be careful about starting an affair - look what happened to me. Think hard about the consequences first, because the most
bizarre things can happen when you least expect it!"
Washington said she will tell her sons about their different DNA when they are old enough to understand. She has no plans to tell the other father,
although she did say "if when he is older Justin wants to meet his real dad then that's his decision".
Although rare in humans, heteropaternal superfecundation is more common in other animals such as cats and dogs, a fact that is well known to
professional breeders. Some kennel clubs for instance allow the registration of litters to more than one male dog or "sire", a phenomenon called
"multi-siring", and you can purchase DNA test kits from them for that purpose.
Sources: myFox DALLAS/FORTWORTH, Daily Mail, American Kennel Club.
: Catharine Paddock, PhD
are only a handful of documented cases in the world.
Their parents Mia Washington and her fianc?©e James Harrison went public with their news last week when they contacted FOX4 to tell their
story.
Admitting she was having an affair with another man at the time the twins were conceived, Washington said she was shocked that it had happened to
her:
"I have twins, but they're by different fathers," she told the TV news company.
Washington and Harrison noticed that the twins had different facial features and decided to have a paternity test. They went to Dallas DNA Lab Clear
Diagnostics who said they had never seen a result like this before and that there was a 99.999 per cent chance that Justin and Jordan were fathered by
different men.
The highly probable result is that Jordan is Harrison's biological son and Justin's biological father is the man Washington had an affair with.
Lab Clear Diagnostics' president Genny Thibodeaux described the news as "very crazy", and "most people don't believe it can happen".
Dr Chris Dreiling, from the Paediatric Association of Dallas, who has not met the family, told Fox News that a woman can release more than one egg
during ovulation, and if she has intercourse with more than one partner at around that time, then sperm from different partners can fertilize each egg:
"Because sperm cells take a while to travel and eggs take a while to travel there can be an overlap," said Dreiling, explaining that it was a very rare
event and likely to be "the only time that we will ever see this occur in the city of Dallas".
Harrison said he will bring up the two boys as his own. He said he has forgiven his fianc?©e and promised to stay with her.
He said they are taking it day by day, "it's going to take time to build that trust like we had", he added.
Washington said she felt wary at first, thinking he would try but then give up and leave. But she said that has not happened.
"James is a good man; he's a great father and genuinely loves both of the twins," said Washington, adding that as far as she was concerned he was the
father of both boys because "he's the one there every morning when they get up and every night when they go to sleep".
Washington said she regrets her mistake and wants other people to know that this can happen.
"Don't put yourself in my shoes, because it can hurt and it does hurt, but you still have to go on with life". She had this advice for other women:
"Be careful about starting an affair - look what happened to me. Think hard about the consequences first, because the most
bizarre things can happen when you least expect it!"
Washington said she will tell her sons about their different DNA when they are old enough to understand. She has no plans to tell the other father,
although she did say "if when he is older Justin wants to meet his real dad then that's his decision".
Although rare in humans, heteropaternal superfecundation is more common in other animals such as cats and dogs, a fact that is well known to
professional breeders. Some kennel clubs for instance allow the registration of litters to more than one male dog or "sire", a phenomenon called
"multi-siring", and you can purchase DNA test kits from them for that purpose.
Sources: myFox DALLAS/FORTWORTH, Daily Mail, American Kennel Club.
: Catharine Paddock, PhD
четверг, 27 октября 2011 г.
Breast Cancer Guidelines Confirm Central Role Of 'Switch Strategy'
Guidelines from the 2007 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, published in the Annals of Oncology (annonc.oxfordjournals), confirm the value of switching from tamoxifen to an aromatase inhibitor (AI), such as exemestane, for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.[i]
Approximately 360,000 women in Europe are diagnosed with breast cancer each year. With up to two thirds of breast cancers requiring the hormone estrogen to grow, medicines such as exemestane are crucial for women affected by this disease, because they work by interfering with the supply of estrogen to the cancer and preventing it from growing. Switching from tamoxifen to exemestane has the potential to save lives among women diagnosed with hormone receptor positive early breast cancer.ii
The St Gallen guidelines are the consensus of breast cancer experts from around the world, who have assessed and recommended optimal treatment strategies for this disease, which affects the lives of thousands of women and their families.
"Guidelines are essential for physicians, as they ensure we are up to date with the latest recommendations for patient care," said Professor Charles Coombes, Head, Department of Oncology, Imperial College, London. "The St Gallen guidelines have confirmed the value of starting treatment with tamoxifen then switching to an aromatase inhibitor, enabling women to benefit from the advantages of both medicines. Exemestane, one of the aromatase inhibitors, has been proven to offer an overall survival benefit in the switch setting, and these latest guidelines confirm to physicians that we should continue to use it in this way to offer patients the very best care."
In hormone receptor positive breast cancer, the St Gallen panel expressed a clear preference for switching patients from tamoxifen to an AI, such as exemestane, which means more patients can benefit from exemestane's proven results in extending lives.
The guidelines follow publication of the Intergroup Exemestane Study (IES) in The Lancet earlier this year, which showed an overall survival benefit for women who switched from tamoxifen to exemestane, the only AI to have demonstrated overall survival in a single, double-blind trial.[ii] The IES, which randomized 4,724 patients across 37 countries, demonstrated that postmenopausal women[1] with early breast cancer, who switched to exemestane after 2-3 years of tamoxifen, experienced a 17% reduction in the risk of death compared to those who stayed on tamoxifen for the full 5 years of therapy.ii Exemestane was the first AI to receive approval in the switch setting.
Professor Coombes, who was lead investigator of the IES, continued, "The IES results, and now the St Gallen guidelines, confirm that switching to exemestane rather than staying on tamoxifen gives women an improved chance of survival. Furthermore, switching to exemestane has also been proven to have no significant adverse effect on quality of life compared to tamoxifen alone,[iii] making it a good all-round option for women."
About exemestane[iv]
Exemestane is currently indicated for the adjuvant treatment of postmenopausal women with estrogen receptor positive invasive early breast cancer who have received 2-3 years of tamoxifen and are switched to exemestane for the completion of a total of 5 consecutive years of adjuvant hormonal therapy. Exemestane is also indicated for the treatment of advanced breast cancer in women with natural or induced postmenopausal states, whose disease has progressed following anti-estrogen therapy.
Exemestane should not be used in women who are premenopausal, are nursing or pregnant, have a known hypersensitivity to the drug, or are taking estrogen-containing agents. Exemestane should be used cautiously with drugs that are metabolised via CYP3A4 and have a narrow therapeutic window.
Exemestane was generally well tolerated across all clinical studies; undesirable effects were usually mild to moderate. The withdrawal rate due to adverse events in studies was 6.3% in patients with early breast cancer receiving adjuvant treatment with exemestane following initial adjuvant tamoxifen therapy and 2.8% in the overall patient population with advanced breast cancer receiving the standard dose of 25 mg. In patients with early breast cancer the most commonly reported adverse reactions were hot flushes (22%), arthralgia (17%) and fatigue (17%). In patients with advanced breast cancer the most commonly reported adverse reactions were hot flushes (14%) and nausea (12%). Most adverse reactions can be attributed to the normal pharmacological consequences of estrogen deprivation (e.g. hot flushes).
pfizeroncology
[i] Women with estrogen receptor positive or unknown status of disease.
[ii] Coombes RC et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007 Feb 17;369(9561):559-70
[iii] Fallowfield LJ et al. Quality of Life in the Intergroup Exemestane Study (IES) - a Randomized Trial of Exemestane versus Continued Tamoxifen after 2-3 years of Tamoxifen in Postmenopausal Women with Primary Breast Cancer. Journal of Clinical Oncology. Vol 24, No 6, Feb 20, 2006
[iv]Exemestane prescribing information (Summary of Product Characteristics dated 24 August 2005)
Approximately 360,000 women in Europe are diagnosed with breast cancer each year. With up to two thirds of breast cancers requiring the hormone estrogen to grow, medicines such as exemestane are crucial for women affected by this disease, because they work by interfering with the supply of estrogen to the cancer and preventing it from growing. Switching from tamoxifen to exemestane has the potential to save lives among women diagnosed with hormone receptor positive early breast cancer.ii
The St Gallen guidelines are the consensus of breast cancer experts from around the world, who have assessed and recommended optimal treatment strategies for this disease, which affects the lives of thousands of women and their families.
"Guidelines are essential for physicians, as they ensure we are up to date with the latest recommendations for patient care," said Professor Charles Coombes, Head, Department of Oncology, Imperial College, London. "The St Gallen guidelines have confirmed the value of starting treatment with tamoxifen then switching to an aromatase inhibitor, enabling women to benefit from the advantages of both medicines. Exemestane, one of the aromatase inhibitors, has been proven to offer an overall survival benefit in the switch setting, and these latest guidelines confirm to physicians that we should continue to use it in this way to offer patients the very best care."
In hormone receptor positive breast cancer, the St Gallen panel expressed a clear preference for switching patients from tamoxifen to an AI, such as exemestane, which means more patients can benefit from exemestane's proven results in extending lives.
The guidelines follow publication of the Intergroup Exemestane Study (IES) in The Lancet earlier this year, which showed an overall survival benefit for women who switched from tamoxifen to exemestane, the only AI to have demonstrated overall survival in a single, double-blind trial.[ii] The IES, which randomized 4,724 patients across 37 countries, demonstrated that postmenopausal women[1] with early breast cancer, who switched to exemestane after 2-3 years of tamoxifen, experienced a 17% reduction in the risk of death compared to those who stayed on tamoxifen for the full 5 years of therapy.ii Exemestane was the first AI to receive approval in the switch setting.
Professor Coombes, who was lead investigator of the IES, continued, "The IES results, and now the St Gallen guidelines, confirm that switching to exemestane rather than staying on tamoxifen gives women an improved chance of survival. Furthermore, switching to exemestane has also been proven to have no significant adverse effect on quality of life compared to tamoxifen alone,[iii] making it a good all-round option for women."
About exemestane[iv]
Exemestane is currently indicated for the adjuvant treatment of postmenopausal women with estrogen receptor positive invasive early breast cancer who have received 2-3 years of tamoxifen and are switched to exemestane for the completion of a total of 5 consecutive years of adjuvant hormonal therapy. Exemestane is also indicated for the treatment of advanced breast cancer in women with natural or induced postmenopausal states, whose disease has progressed following anti-estrogen therapy.
Exemestane should not be used in women who are premenopausal, are nursing or pregnant, have a known hypersensitivity to the drug, or are taking estrogen-containing agents. Exemestane should be used cautiously with drugs that are metabolised via CYP3A4 and have a narrow therapeutic window.
Exemestane was generally well tolerated across all clinical studies; undesirable effects were usually mild to moderate. The withdrawal rate due to adverse events in studies was 6.3% in patients with early breast cancer receiving adjuvant treatment with exemestane following initial adjuvant tamoxifen therapy and 2.8% in the overall patient population with advanced breast cancer receiving the standard dose of 25 mg. In patients with early breast cancer the most commonly reported adverse reactions were hot flushes (22%), arthralgia (17%) and fatigue (17%). In patients with advanced breast cancer the most commonly reported adverse reactions were hot flushes (14%) and nausea (12%). Most adverse reactions can be attributed to the normal pharmacological consequences of estrogen deprivation (e.g. hot flushes).
pfizeroncology
[i] Women with estrogen receptor positive or unknown status of disease.
[ii] Coombes RC et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007 Feb 17;369(9561):559-70
[iii] Fallowfield LJ et al. Quality of Life in the Intergroup Exemestane Study (IES) - a Randomized Trial of Exemestane versus Continued Tamoxifen after 2-3 years of Tamoxifen in Postmenopausal Women with Primary Breast Cancer. Journal of Clinical Oncology. Vol 24, No 6, Feb 20, 2006
[iv]Exemestane prescribing information (Summary of Product Characteristics dated 24 August 2005)
четверг, 20 октября 2011 г.
FDA To Conduct Surveys About STI, Pregnancy Prevention Language On Condom Packaging
FDA plans to survey 1,200 people in shopping malls nationwide on their understanding of a condom's efficacy in preventing sexually transmitted infections, including HIV, and unplanned pregnancies based on current labeling, the agency said on Thursday in a notice on its Web site, Bloomberg/Arizona Republic reports. According to the notice, survey responses will be "considered in FDA's condom labeling recommendations to provide important risk/benefit and use information associated with condoms in easily understood language."
Congress in 2000 directed FDA to "determine whether [condom] labels are medically accurate regarding the overall effectiveness or lack of effectiveness," Bloomberg/Republic reports. The agency in a 2005 review found that many people who use condoms are unsure how often the contraceptive fails to prevent pregnancy with typical use or that they provide less protection from certain STIs, such as genital herpes, Bloomberg/Republic reports. FDA in 2005 also proposed that labels on condom boxes and wrappers show data on unplanned pregnancies and varying levels of protection against STIs (Bloomberg/Arizona Republic, 6/14).
In addition, the agency in November 2005 published a draft guidance document for latex condom manufacturers. The document included a proposal that labels be required to state that condoms "greatly reduce but do not eliminate" the risk of pregnancy and HIV infection when used correctly during sexual intercourse but provide "less protection" from other STIs, including human papillomavirus and herpes, because those STIs can be spread through skin-to-skin contact. However, the guidance also says that "using latex condoms every time you have sex may still give you some benefits against these" STIs (Kaiser Daily HIV/AIDS Report, 6/22/06). FDA also recommended that condoms with spermicidal lubricant nonoxynol-9 include a warning that the lubricant can cause irritation that raises the risk of HIV transmission.
Any label changes would apply only to male condoms made with natural rubber latex, which account for almost 98% of sales in the U.S., FDA said. Guidelines for products made with lambskin or synthetic materials will be issued at a later date, the agency said (Bloomberg/Arizona Republic, 6/14).
"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Congress in 2000 directed FDA to "determine whether [condom] labels are medically accurate regarding the overall effectiveness or lack of effectiveness," Bloomberg/Republic reports. The agency in a 2005 review found that many people who use condoms are unsure how often the contraceptive fails to prevent pregnancy with typical use or that they provide less protection from certain STIs, such as genital herpes, Bloomberg/Republic reports. FDA in 2005 also proposed that labels on condom boxes and wrappers show data on unplanned pregnancies and varying levels of protection against STIs (Bloomberg/Arizona Republic, 6/14).
In addition, the agency in November 2005 published a draft guidance document for latex condom manufacturers. The document included a proposal that labels be required to state that condoms "greatly reduce but do not eliminate" the risk of pregnancy and HIV infection when used correctly during sexual intercourse but provide "less protection" from other STIs, including human papillomavirus and herpes, because those STIs can be spread through skin-to-skin contact. However, the guidance also says that "using latex condoms every time you have sex may still give you some benefits against these" STIs (Kaiser Daily HIV/AIDS Report, 6/22/06). FDA also recommended that condoms with spermicidal lubricant nonoxynol-9 include a warning that the lubricant can cause irritation that raises the risk of HIV transmission.
Any label changes would apply only to male condoms made with natural rubber latex, which account for almost 98% of sales in the U.S., FDA said. Guidelines for products made with lambskin or synthetic materials will be issued at a later date, the agency said (Bloomberg/Arizona Republic, 6/14).
"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
четверг, 13 октября 2011 г.
LA Times Examines Health Risks of, Alternatives to Hysterectomy
The LA Times on Monday examined the health risks of undergoing a hysterectomy and how many women's health experts increasingly are questioning the need for many of the 615,000 procedures that are performed annually in the U.S. The rate of hysterectomies performed in the U.S. decreased from 45.7 per 10,000 women in 2002 to 41.7 in 2003, according to the American College of Obstetricians and Gynecologists. More than 90% of hysterectomies performed in the U.S. are conducted because a woman has fibroids, endometriosis, abnormal bleeding, or a prolapsed or fallen uterus -- all conditions for which less-invasive surgery or nonsurgical treatments are available (Foreman, Los Angeles Times, 8/15). According to a study conducted by William Parker, a clinical professor at the University of California-Los Angeles David Geffen School of Medicine, and colleagues and published in the Aug. 1 issue of Obstetrics & Gynecology, more than half of the women who undergo hysterectomy each year in the U.S. also have their ovaries removed in order to eliminate their risk of developing ovarian cancer. However, the prophylactic removal of the ovaries -- which continue to produce small amounts of hormones even after a woman experiences menopause -- does not provide a health benefit, regardless of a woman's age at surgery, the study found. In addition, women who have their ovaries removed before age 65 might be at increased risk of heart disease because of a lack of estrogen in the body, Parker said. Overall, the younger a woman is when she has her ovaries removed, the more substantial the negative impact on her health and her chances of living to age 80 (Kaiser Daily Reproductive Health Report, 8/2). Some health advocates suggest that women seek alternative treatments to hysterectomy, such as myomectomy, the surgical removal of fibroids without removing the uterus; uterine artery embolization, which involves inserting small plastic pellets into blood vessels to cut off blood supply; or laparoscopic surgery, in which surgery to remove ovarian tumors is performed through a keyhole incision (Foreman, Los Angeles Times, 8/15).
Los Angeles Times
"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Los Angeles Times
"Reprinted with permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
четверг, 6 октября 2011 г.
More About Sex And Relationships Needed At Gynaecological Visits
Visits to a gynaecologist or midwife are generally associated with different tests and/or prescriptions for contraceptives, but could offer so much more. Women, doctors and midwives are agreed that gynaecological visits presents great opportunities for dialogue about sexual health, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.
Many young women see sex as a problem, the thesis shows. Almost 500 women aged 23-29 answered questions about their sex lives, their relationships and how they view gynaecological visits. One in five had a reduced sex drive and found it difficult to be satisfied together with their partner. Just as many said that they had been taken advantage of sexually or experienced other forms of sexual abuse.
"Many young women actually know little about their sexuality," says midwife Eva Wendt, who wrote the thesis. "If you feel confident about your body and understand how it works, sex is much easier and much more fun."
Nine out of ten young women think it natural to be asked questions about sexuality at a visit to a gynaecologist or midwife, the survey shows. Seven out of ten think it natural to be asked questions about sexual abuse.
"Women trust their doctor and their midwife - they are independent parties who have both expertise and a duty of confidentiality," says Wendt. "This paves the way for a dialogue when these professionals ask questions and can help women to reflect and see their own situation more clearly."
This view is shared by midwives, general practitioners and gynaecologists, but it is still relatively unusual for medical professionals to invite women to engage in in depth discussion of sexuality and relationships. Instead, visits are primarily medically oriented discussion of sexuality gets forgotten or time runs out.
"Both doctors and midwives describe opportunities to create respectful meetings and strengthen women by giving them information and encouraging them to have a positive view of sexuality," says Wendt. "Now that we know that women and medical professionals both want the same thing, perhaps sexuality and dialogue with the patient can be allotted more time at gynaecological visits."
Source: University of Gothenburg
Many young women see sex as a problem, the thesis shows. Almost 500 women aged 23-29 answered questions about their sex lives, their relationships and how they view gynaecological visits. One in five had a reduced sex drive and found it difficult to be satisfied together with their partner. Just as many said that they had been taken advantage of sexually or experienced other forms of sexual abuse.
"Many young women actually know little about their sexuality," says midwife Eva Wendt, who wrote the thesis. "If you feel confident about your body and understand how it works, sex is much easier and much more fun."
Nine out of ten young women think it natural to be asked questions about sexuality at a visit to a gynaecologist or midwife, the survey shows. Seven out of ten think it natural to be asked questions about sexual abuse.
"Women trust their doctor and their midwife - they are independent parties who have both expertise and a duty of confidentiality," says Wendt. "This paves the way for a dialogue when these professionals ask questions and can help women to reflect and see their own situation more clearly."
This view is shared by midwives, general practitioners and gynaecologists, but it is still relatively unusual for medical professionals to invite women to engage in in depth discussion of sexuality and relationships. Instead, visits are primarily medically oriented discussion of sexuality gets forgotten or time runs out.
"Both doctors and midwives describe opportunities to create respectful meetings and strengthen women by giving them information and encouraging them to have a positive view of sexuality," says Wendt. "Now that we know that women and medical professionals both want the same thing, perhaps sexuality and dialogue with the patient can be allotted more time at gynaecological visits."
Source: University of Gothenburg
Подписаться на:
Сообщения (Atom)